Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Photodiagnosis Photodyn Ther. 2023 Dec;44:103807. doi: 10.1016/j.pdpdt.2023.103807. Epub 2023 Sep 20.
Central serous chorioretinopathy (CSC) is characterized by focal serous detachment of the retina, primarily affecting the macula. Photodynamic therapy (PDT) is the best choice for treatment of chronic and recurrent patients. In this study we aim to evaluate the early effects of the half dose protocol (3 mg/m verteporfine) of PDT laser treatment on the micro vasculature of choroid.
Among thirty-one patients (62 eyes), twenty eyes were in the control group and forty-two eyes received PDT laser treatment. Vision log MAR, CMT (central macular thickness), SRF (sub retinal fluid), BCT (baseline choroidal thickness), CVI (choroidal vascular index), and laser treated area were compared between two groups.
Results show that no strong correlation was detected between the impact of laser treatment and resolution of SRF in the first week in the fovea. The mean best corrected visual acuity (BCVA) of the patients significantly increased from 20/63 at the beginning of the study, according to the Snellen chart, to 20/49 in the first week and 20/38 in the sixth week. PDT can significantly reduce SRF and CMT in 6 weeks compared to the control group. Although there was initially a small, non-statistically significant increase in choroidal thickness and CVI after 1 week, a dramatic decrease occurs after 6 weeks. Therefore, after 6 weeks of PDT laser, all the indicators such as SRF, CMT, choroidal thickness, and CVI significantly reduced.
PDT laser can significantly reduce SRF and CMT at 1 and 6 weeks and choroidal thickness and CVI at 6 weeks in chronic CSC patients. Also, a larger laser treated area has no impact on the final outcome. Therefore, it seems that the mechanism of PDT in CSC disease is the recovery of choriocapillaris circulation.
中心性浆液性脉络膜视网膜病变(CSC)的特征是视网膜局部浆液性脱离,主要影响黄斑。光动力疗法(PDT)是治疗慢性和复发性患者的最佳选择。在这项研究中,我们旨在评估 PDT 激光治疗半剂量方案(3mg/m2 维替泊芬)对脉络膜微血管的早期影响。
在 31 名患者(62 只眼)中,20 只眼为对照组,42 只眼接受 PDT 激光治疗。比较两组之间的视力 logMAR、CMT(中心黄斑厚度)、SRF(视网膜下液)、BCT(基线脉络膜厚度)、CVI(脉络膜血管指数)和激光治疗区域。
结果表明,在治疗后的第一周,激光治疗对黄斑中心凹 SRF 消退的影响与激光治疗面积之间没有很强的相关性。根据 Snellen 图表,患者的最佳矫正视力(BCVA)平均值从研究开始时的 20/63 显著增加,第一周为 20/49,第六周为 20/38。与对照组相比,PDT 可在 6 周内显著减少 SRF 和 CMT。尽管在第 1 周后,脉络膜厚度和 CVI 最初略有、非统计学意义上的增加,但在第 6 周后会急剧下降。因此,在 PDT 激光治疗 6 周后,所有指标如 SRF、CMT、脉络膜厚度和 CVI 均显著降低。
PDT 激光治疗可显著减少慢性 CSC 患者在 1 周和 6 周时的 SRF 和 CMT,以及在 6 周时的脉络膜厚度和 CVI。此外,更大的激光治疗面积对最终结果没有影响。因此,PDT 在 CSC 疾病中的作用机制似乎是脉络膜毛细血管循环的恢复。